SGP SpyGlass Pharma, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1778922 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-33.5%
ROA-31.1%
ROIC (approx.)-3,475.3%
Asset turnover—
Leverage & solvency
Liabilities / assets7.0%
Debt / equity0.00x
Current ratio15.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | — | — | — | — |
| R&D expense | $10.03M | $10.94M | $8.54M | $7.71M | $8.09M | $7.33M | $6.05M |
| SG&A expense | $16.21M | $11.03M | $6.87M | $5.92M | $3.01M | $1.96M | $1.37M |
| Operating income | -$26.25M | -$21.97M | -$15.41M | -$13.63M | -$11.10M | -$9.30M | -$7.42M |
| Pretax income | -$24.25M | -$19.86M | -$13.82M | -$12.55M | -$9.82M | -$8.68M | -$8.82M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$24.25M | -$19.86M | -$13.82M | -$12.55M | -$9.82M | -$8.68M | -$8.82M |
| EBITDA | -$25.96M | -$21.63M | -$15.09M | -$13.41M | -$10.96M | -$9.16M | -$7.30M |
| EPS (basic) | -0.73 | -0.59 | -0.69 | — | -4.53 | -3.81 | -3.96 |
| EPS (diluted) | -0.73 | -0.59 | -0.69 | — | -4.53 | -3.81 | -3.96 |
| Weighted avg. shares (diluted) | 33.45M | 33.44M | 19.93M | — | 2.17M | 2.28M | 2.23M |
| Balance sheet | |||||||
| Cash & equivalents | $208.69M | $223.14M | $238.90M | $96.36M | $106.01M | $127.23M | $58.00M |
| Current assets | $217.91M | $236.46M | $253.36M | $108.77M | — | — | — |
| PP&E, net | $6.34M | $4.79M | $2.75M | $2.34M | — | — | — |
| Total assets | $226.35M | $243.43M | $258.39M | $115.87M | — | — | — |
| Current liabilities | $14.30M | $9.44M | $6.67M | $8.58M | — | — | — |
| Total liabilities | $15.91M | $11.07M | $8.27M | $10.17M | — | — | — |
| Shareholders' equity | $210.44M | $232.36M | $250.11M | -$98.84M | -$87.22M | -$78.38M | -$68.85M |
| Shares outstanding | 33.46M | 33.45M | 33.43M | 2.20M | — | — | — |
| Cash flow statement | |||||||
| Operating cash flow | -$16.02M | -$14.84M | -$13.54M | -$9.34M | -$8.84M | -$6.33M | -$8.20M |
| Capital expenditure | $2.46M | $1.93M | $676,000 | $421,000 | $152,000 | $52,000 | $164,000 |
| Free cash flow | -$18.48M | -$16.77M | -$14.22M | -$9.76M | -$8.99M | -$6.38M | -$8.37M |
| Investing cash flow | $1.54M | -$933,000 | -$1.67M | $574,000 | -$12.15M | -$52,000 | -$164,000 |
| Financing cash flow | $27,000 | $13,000 | $157.75M | -$888,000 | -$236,000 | $75.61M | $50.10M |
| Depreciation & amortization | $280,000 | $341,000 | $318,000 | $217,000 | $137,000 | $135,000 | $124,000 |
| Stock-based compensation | $2.30M | $2.10M | $1.68M | $922,000 | $900,000 | $600,000 | $345,000 |
| Share buybacks | $0 | — | — | $0 | $0 | — | — |
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.